Annexin Pharmaceuticals AB (publ) (STO:ANNX)
Sweden flag Sweden · Delayed Price · Currency is SEK
15.00
+0.10 (0.67%)
Feb 11, 2026, 4:05 PM CET

STO:ANNX Cash Flow Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-36.89-50.25-44.05-40.73-52.14
Depreciation & Amortization
-0.190.190.190.19
Other Operating Activities
0.1900-5.19
Change in Accounts Payable
0.01-1.371-0.180.61
Change in Other Net Operating Assets
-0.241.2-0.54-0.451.13
Operating Cash Flow
-36.93-50.23-43.4-41.17-45.02
Capital Expenditures
-0.13----
Investment in Securities
--0.1-0.26-
Investing Cash Flow
-0.13-0.1-0.26-
Long-Term Debt Issued
-510-20
Net Debt Issued (Repaid)
-510-20
Issuance of Common Stock
49.9740.0626.523.1166.66
Other Financing Activities
-1.860.1-2.9-0.05-10.29
Financing Cash Flow
48.1145.1533.6123.0676.37
Miscellaneous Cash Flow Adjustments
--0-0--
Net Cash Flow
11.06-5.08-9.7-18.3731.35
Free Cash Flow
-37.05-50.23-43.4-41.17-45.02
Free Cash Flow Per Share
-5.60-11.11-25.97-28.14-54.88
Cash Interest Paid
-0.050--
Levered Free Cash Flow
-23.05-31.48-26.87-26.05-28.92
Unlevered Free Cash Flow
-23.05-31.48-26.87-26.05-27.76
Change in Working Capital
-0.23-0.170.46-0.631.74
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.